Targeted Protein Degraders (TPD) | Global Pipeline

Last Update: Aug 6, 2023

Click to purchase the complete TPD database, including companies with pre-clinical programs (80+ rows) and additional notes.



Company Type Candidate MOA/Platform Indications Stage Trial Trial Initiation
Bristol Myers SquibbPublicIberdomide IKZF1/3 molecular glue degraderMultiple myeloma (MM)IIINCT04975997July 2022
Bristol Myers SquibbPublicCC-92480IKZF1/3 molecular glue degraderMMIIINCT03989414Sep 2019
Bristol Myers SquibbPublicCC-99282IKZF1/3 molecular glue degraderr/r NHLIINCT03930953May 2019
ArvinasPublicBavdegalutamidePROTAC targeting ARmCRPCIINCT03888612March 2019
Arvinas & PfizerPublicARV-471PROTAC targeting ERER+ HER2- metastatic BC (+- Ibrance)IINCT04072952Aug 2019
ArvinasPublicARV-766PROTAC targeting ARmCRPCIINCT05067140Sep 2021
Ranok TherapeuticsPrivateRNK05047BRD4-targeting protein degrader (chaperone-mediated)Advanced solid tumors or DLBCLI/IINCT05487170Aug 24 2022
C4 TherapeuticsPublicCFT7455IKZF1/3 molecular glue degraderr/r NHL or MMI/IINCT04756726June 2021
NovartisPublicDKY709IKZF2 molecular glue degraderAdvanced solid tumors (NSCLC, Melanoma, CRC, TNBC)I/IbNCT03891953May 2019
Kangpu BiopharmaceuticalsPrivateKPG-818IKZF1/3 molecular glue degrader (lenalidomide analog)SLEIIaNCT04643067June 2022
Bristol Myers SquibbPublicCC-90009GSPT1 molecular glue degraderAML (combo therapy)IbNCT04336982Aug 2020
Bristol Myers SquibbPublicCC-94676PROTAC targeting ARmCRPCINCT04428788Jun 2020
Kymera Therapeutics & SanofiPublicKT-474PROTAC targeting IRAK4IL-1R/TLR-driven diseases (HS, AD)INCT04772885Feb 2021
Nurix TherapeuticsPublicNX-2127PROTAC targeting BTK + IKZF1/3CLL, SLL, WM, MCL, MZL, FL, DLBCLINCT04830137May 2021
Foghorn TherapeuticsPublicFHD-609PROTAC targeting BRD9Advanced synovial sarcoma, SMARCB1-deleted tumorsINCT04965753Aug 2021
Dialectic TherapeuticsPrivateDT2216PROTAC targeting BCL-XLr/r Solid tumors + Hematological malignanciesINCT04886622Oct 2021
Bristol Myers SquibbPublicBMS-986397CK1α molecular glue degraderr/r AML, MDSINCT04951778Dec 2021
Kangpu BiopharmaceuticalsPrivateKPG-818IKZF1/3 molecular glue degraderHematological malignanciesINCT04283097May 2020
Kangpu BiopharmaceuticalsPrivateKPG-121CK1α molecular glue degradermCRPCINCT03569280Nov 2019
Haisco Pharmaceutical GroupPublicHSK29116PROTAC targeting BTKr/r B cell malignanciesINCT04861779Aug 2021
Kymera TherapeuticsPublicKT-413PROTAC targeting IRAK4 + IKZF1/3MYD88-mutant tumorsINCT05233033June 2022
Kymera TherapeuticsPublicKT-333PROTAC targeting STAT3r/r NHL, PTCL, CTCL, LGL-L, Solid tumorsINCT05225584Jan 2022
BioTheryXPrivateBTX-1188GSTP1 + IKZF1/3 molecular glue degraderHematological malignancies (NHL, AML), Solid tumorsINCT05144334Jan 2022
C4 TherapeuticsPublicCFT8634PROTAC targeting BRD9Metastatic SMARCB1-perturbed cancers (synovial sarcoma, SMARCB1-null tumors)I/IINCT05355753March 2022
Nurix TherapeuticsPublicNX-5948PROTAC targeting BTKCLL, SLL, DLBCL, FL, MCL, MZL, WM, PCNSLINCT05131022Apr 2022
Hinova PharmaceuticalsPrivateHP518PROTAC targeting ARmCRPCINCT05252364Feb 2022
Kintor PharmaceuticalPublicGT20029PROTAC targeting AR (topical formulation)Androgenic alopecia, Acne vulgarisINCT05428449Feb 2022
Astellas PharmaPublicASP3082PROTAC targeting KRAS G12DAdvanced/metastatic r/r solid tumors with KRAS G12D mutationsINCT05382559Jun 2022
Orum TherapeuticsPrivateORM-5029GSPT1 molecular glue degrader-anti-HER2 mAb (pertuzumab) conjugateHER2-expressing advanced solid tumorsINCT05511844Oct 2022
Monte Rosa TherapeuticsPublicMRT-2359GSPT1 molecular glue degraderMyc-driven NSCLC, SCLC, DLBCL, high-grade neuroendocrine cancer, solid tumorsI/IINCT05546268Nov 2022
C4 TherapeuticsPublicCFT1946PROTAC targeting BRAF V600XBRAF V600X driven cancers (melanoma, CRC, NSCLC)I/IINCT05668585Dec 2022
Accutar BiotechPrivateAC0682PROTAC targeting ERαER+ breast cancerINCT05080842Nov 2021
Accutar BiotechPrivateAC0176PROTAC targeting ARMetastatic castration-resistant prostate cancerINCT05241613Feb 2023
Prelude TherapeuticsPublicPRT3789SMARCA2 degraderSMARCA4-mutated NSCLC and other tumorsINCT05639751Feb 2023
Accutar BiotechPrivateAC0676PROTAC targeting BTKB cell malignanciesINCT05780034Q2-Q3
Autotac BioPrivateATC-102AUTOTAC targeting TauAlzheimer's diseaseI--
CullgenPrivateCG001419TRK degraderNTRK fusion-positive cancersIND cleared--


FULL DATABASE